You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

AITL

Showing 1 - 25 of 37
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

NK/T Cell Lymphoma, Vascular Immunomother T Cell Lymphoma, Non-Hodgkin Lymphoma Trial in Guangzhou (GNC-038)

Not yet recruiting
  • NK/T Cell Lymphoma
  • +2 more
  • Guangzhou, Guangdong, China
  • +1 more
Jan 12, 2023

Refractory T-Cell Lymphoma, Relapsed T-Cell Lymphoma Trial in Italy (Daratumumab)

Active, not recruiting
  • Refractory T-Cell Lymphoma
  • Relapsed T-Cell Lymphoma
  • Bari, Italy
  • +6 more
Aug 1, 2022

T-Cell Lymphoma Relapsed, T-Cell Lymphoma Refractory Trial in Italy (Venetoclax)

Active, not recruiting
  • T-Cell Lymphoma Relapsed
  • T-Cell Lymphoma Refractory
  • Aviano, Italy
  • +12 more
Dec 20, 2022

Angioimmunoblastic T-cell Lymphoma Trial in Guangzhou (Sintilimab, Chidamide)

Not yet recruiting
  • Angioimmunoblastic T-cell Lymphoma
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Apr 2, 2021

T-cell Lymphoma Trial in Belgium, France (Lenalidomide)

Completed
  • T-cell Lymphoma
  • Bruxelles, Belgium
  • +29 more
Jul 23, 2021

Relapsed Angioimmunoblastic T-Cell Lymphoma, Refractory Angioimmunoblastic T-cell Lymphoma Trial in Worldwide (Oral azacitidine,

Active, not recruiting
  • Relapsed Angioimmunoblastic T-Cell Lymphoma
  • Refractory Angioimmunoblastic T-cell Lymphoma
  • Oral azacitidine
  • +3 more
  • Graz, Austria
  • +33 more
Aug 24, 2022

Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Grade 1

Active, not recruiting
  • Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
  • +18 more
  • Anti-ICOS Monoclonal Antibody MEDI-570
  • +2 more
  • Duarte, California
  • +22 more
Jan 18, 2023

Peripheral T Cell Lymphoma, PTCL, Extranodal NK/T-cell Lymphoma Trial in Worldwide (Tislelizumab)

Completed
Has Results
  • Peripheral T Cell Lymphoma
  • +18 more
  • Vancouver, British Columbia, Canada
  • +29 more
Apr 29, 2022

Peripheral T-Cell Lymphoma (PTCL NOS), Nodal Lymphomas of T Follicular Helper (TFH), Follicular T-cell Lymphoma (FTCL) Trial

Withdrawn
  • Peripheral T-Cell Lymphoma (PTCL NOS)
  • +8 more
  • (no location specified)
Mar 10, 2020

T-Cell Lymphoma, Peripheral T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma Refractory Trial in United States (LB1901)

Active, not recruiting
  • T-Cell Lymphoma
  • +4 more
  • LB1901
  • Rochester, Minnesota
  • +3 more
Feb 15, 2022

T-Cell Tumor, Lymphoproliferative Disorders Trial in Ann Arbor (Pacritinib)

Not yet recruiting
  • T-Cell Neoplasm
  • Lymphoproliferative Disorders
  • Ann Arbor, Michigan
    University of Michigan Rogel Cancer Center
Oct 6, 2022

T-cell Lymphoma, Cutaneous/Peripheral T-Cell Lymphoma, Peripheral T-cell Lymphoma Trial in Chicago (Fenretinide)

Not yet recruiting
  • T-cell Lymphoma
  • +10 more
  • Chicago, Illinois
    Rush University Medical Center
Oct 24, 2022

Relapsed or Refractory T Cell Lymphoma Trial in United States (ONO-4685)

Recruiting
  • Relapsed or Refractory T Cell Lymphoma
  • Birmingham, Alabama
  • +10 more
Sep 20, 2022

Lymphoma Trial in Worldwide (plitidepsin)

Terminated
Has Results
  • Lymphoma
  • Chicago, Illinois
  • +16 more
Sep 18, 2020

Newly Diagnosed Peripheral T-cell Lymphoma Trial in Nanjing (CMOP+Chidamide)

Recruiting
  • Newly Diagnosed Peripheral T-cell Lymphoma
  • Nanjing, Jiangsu, China
    Hematological Department, People's Hospital of Jiangsu Province
Jun 1, 2023

Relapsed or Refractory Peripheral T-Cell Lymphoma Trial in Korea, Republic of, Spain, United States (Tipifarnib)

Completed
  • Relapsed or Refractory Peripheral T-Cell Lymphoma
  • Palo Alto, California
  • +12 more
Apr 26, 2021

A Study of Chinese Adults With Lymphoma

Recruiting
  • Lymphoma
    • Beijing, Beijing, China
    • +18 more
    Nov 3, 2022

    Isocitrate Dehydrogenase Gene Mutation Trial in Spain, United States (HMPL-306)

    Recruiting
    • Isocitrate Dehydrogenase Gene Mutation
    • Atlanta, Georgia
    • +6 more
    Feb 22, 2022

    Peripheral T-cell Lymphoma Trial in Shanghai (PD-1 antibody+ HDAC inhibitor)

    Recruiting
    • Peripheral T-cell Lymphoma
    • PD-1 antibody+ HDAC inhibitor
    • Shanghai, Shanghai, China
      Dongmei Ji
    Dec 3, 2021

    Epstein-Barr Virus Associated Lymphoproliferative Disorder, EBV-Related PTLD, EBV Related Non-Hodgkin's Lymphoma Trial in

    Recruiting
    • Epstein-Barr Virus Associated Lymphoproliferative Disorder
    • +7 more
    • Nanatinostat in combination with valganciclovir
    • Birmingham, Alabama
    • +57 more
    Aug 10, 2022

    Peripheral T-cell Lymphomas (PTCL) Trial in Taiwan (Lenalidomide and Gemcitabine (Dose level 11), Lenalidomide and Gemcitabine

    Not yet recruiting
    • Peripheral T-cell Lymphomas (PTCL)
    • Lenalidomide and Gemcitabine (Dose level 11)
    • +3 more
    • Kaohsiung, Taiwan
    • +3 more
    Nov 1, 2021

    Lymphoma Trial in Berne (Brentuximab Vedotin, BeEAM Regimen)

    Recruiting
    • Lymphoma
    • Brentuximab Vedotin
    • BeEAM Regimen
    • Berne, Switzerland
      Department for Medical Oncology University Hospital/Inselspital
    Feb 4, 2022

    T-Cell Lymphoma Trial (Brentuximab vedotin, Pembrolizumab)

    Not yet recruiting
    • T-Cell Lymphoma
    • (no location specified)
    Jul 22, 2022

    A Study of People With CD30 Positive Lymphoma in China

    Not yet recruiting
    • Lymphoma
      • (no location specified)
      Aug 17, 2022

      Peripheral T-cell Lymphoma Trial in Singapore (Selinexor, ICE Chemotherapy)

      Completed
      • Peripheral T-cell Lymphoma
      • Singapore, Singapore
        National Cancer Centre Singapore
      Apr 27, 2021